Vaccine Contract Development And Manufacturing Organization Market Size (2024 - 2029)

Vaccine Contract Development And Manufacturing Organization Market Analysis

The Vaccine Contract Development And Manufacturing Organization Market size is estimated at USD 3.26 billion in 2024, and is expected to reach USD 6.21 billion by 2029, growing at a CAGR of 11.5% during the forecast period (2024-2029).

The vaccine development process necessitates significant investments in specialized infrastructure, expertise, and intricate R&D and production protocols. Vaccine manufacturing is subject to rigorous regulations, and intensifying regulatory measures make it increasingly challenging for developers to build internal capabilities for large-scale production of proprietary vaccine candidates while adhering to evolving standards. As a result, CDMO services for vaccine development and manufacturing operations have become a preferred practice in the pharmaceutical industry.

Infectious diseases are spread via bacteria, viruses, fungi, or parasites that are passed, directly or indirectly, from one person to another, such as Chickenpox (Varicella), Dengue, Diphtheria, Ebola, Hepatitis, Hib Disease, HIV/AIDS, and COVID-19. An increase in contagious diseases will demand accurate clinical trials to understand the outcome correctly. For instance, according to the European Centre for Disease Prevention and Control's (ECDC) January 2024 update, over six million dengue cases were reported in 2023 from 92 countries and territories in Europe.

Similarly, according to the World Health Organization HIV/AIDS Surveillance in Europe: 2022 data, an estimated 107,000 individuals were diagnosed with HIV in Europe in 2022. The vast prevalence of infectious diseases such as HIV is anticipated to drive market growth due to the increased adoption of CRO services for HIV drugs. Thus, considering the high prevalence of infectious diseases, the demand for accurate research and manufacturing will likely rise, leading to market growth between 2024 and 2029.

The growing awareness about the advantages of vaccination, such as protection from severe illnesses and infectious diseases, is fueling the demand for immunization programs and vaccinations. Leading pharmaceutical companies are outsourcing vaccine manufacturing due to the complexity of capital requirements for production. Additionally, in April 2022, Japan launched a new research and development center for USD 1.6 billion to support vaccine and drug projects as a part of a project to tackle infectious diseases. Launching a new research and development center in Japan dedicated to vaccine and drug projects against contagious diseases will likely impact the CRO market positively. It is expected to drive increased demand for outsourcing services, attract government funding for research and development, and foster international collaborations. Hence, it is anticipated to fuel the market growth between 2024 and 2029.

The expansion of vaccine manufacturing plants by the CDMO players is expected to boost the market between 2024 and 2029. For instance, in September 2023, WuXi Vaccines launched its first standalone vaccine CDMO site in Suzhou, China. The 8,500 sq.m vaccine manufacturing site near Shanghai employs up to five hundred people.

Additionally, strategic collaboration by the market players is anticipated to boost market growth from 2024 to 2029. For instance, in February 2023, AGC Biologics announced an expanded partnership to support BioNTech Omicron-based vaccine candidates with pDNA starting material at the company’s Heidelberg facility.

Hence, the growing trend of outsourcing, growing awareness of the benefits of vaccines, and strategic collaboration are expected to boost the market between 2024 and 2029. However, limited outsourcing by well-established vaccine manufacturers is expected to restrain the market.

Vaccine Contract Development And Manufacturing Organization Industry Segmentation

As per the scope of the report, the vaccine contract development and manufacturing organization is composed of specialized companies that provide services to pharmaceutical and biotechnology companies involved in the development and manufacturing of vaccines. These CDMOs offer a range of tailored services, from early-stage development to large-scale production, to support the entire vaccine development process. This includes services such as formulation development, process optimization, analytical testing, stability studies, and clinical trial material manufacturing. The primary goal of vaccine CDMOs is to assist their clients in efficiently and safely bringing vaccines from research and development stages to market-ready products, often meeting strict regulatory and quality standards.

The vaccine contract development and manufacturing organization market is segmented by vaccine type, process, scale of operations, and geography. By vaccine type, the market is segmented as inactivated vaccines, live-attenuated vaccines, RNA vaccines, subunit vaccines, and toxoid-based vaccines. By process, the market is segmented as downstream and upstream. By scale of operations, the market is segmented as preclinical, clinical, and commercialization. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.